At the news
? BEARISHIMPACT 7/10 PRESS-RELEASE filed Apr 16, 2026 at 16:05 ET
Emergent BioSolutions announced a $150 million term loan refinancing with OrbiMed and an amended $50 million ABL facility, extending maturities to April 2031 and reducing interest expense by 200 basis points. The move strengthens liquidity but follows a significant earnings miss.
- Closed on a new $150 million term loan with OrbiMed, replacing prior debt from Oak Hill Advisors
- Amended ABL facility with Wells Fargo to extend borrowing capacity of $50 million through April 2031
- Interest expense reduced by 200 basis points annually
- Maturities extended from 2029 to 2031 for both facilities
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access